NRXN1 and epilepsy: In a wide systemic review of individuals with NRXN1 deletions, Castronovo et al. [1] describe the presence of moderate to severe ID in 77–92%, ASD in 43–70%, attention deficit hyperactivity-disorder (ADHD) in 9–41%, anxiety in 6–7%, schizophrenia in 5%, epilepsy in 14–53%, and hypotonia in 38–47% of the cases.